TAINAN, Taiwan, July 08, 2025 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced that it will hold a conference call with investors and analysts on Thursday, August 7, 2025, at 8:00 a.m. US Eastern Daylight Time and 8:00 p.m. Taiwan Time to discuss the Company's second quarter 2025 financial results. HIMAX TECHNOLOGIES, INC. SECOND QUARTER 2025 EARNINGS CONFERENCE ...

THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, elaborates on the Company’s recently announced planned follow-on market expansion study phase (“PoC 2”) of its proof-of-concept trial. The CEO Corner segme ...

CLEVELAND, June 30, 2025 /PRNewswire/ -- TransDigm Group Incorporated (NYSE: TDG) today announced it has entered into a definitive agreement to acquire the Simmonds Precision Products, Inc. Business ("Simmonds" or "the Company") of Goodrich Corporation from RTX Corporation (NYSE: RTX) for approximately $765 million in cash, including certain tax benefits. Simmonds, headquartered in Vergennes, Vermont, is a leading global designer and manufacturer of fuel & proximity sensing and structural health monitoring ...

As previously announced, based on the positive results demonstrated in the initial phase of the Company's first- in-human proof-of-concept study ("PoC 1") in patients with severe pancreatic cancer pain, Autonomix has initiated a follow-on PoC 2 phase in a market expansion opportunity, which doubles the potential addressable market beyond pancreatic cancer pain by evaluating additional visceral cancers that signal pain through the Celiac Plexus and earlier stage pancreatic cancers with moderate to severe pai ...

Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced ...

Investor Presentation February 2020 Forward Looking Statements This presentation contains statements that are, or may be deemed to be, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, any financial or other guidance, statements that reflect our current expectations concerning future results and events, and any other statements that are not based solely on historical fact. Forward-looking s ...

2 Solid Foundation With Opportunities For Growth The information provided in this presentation includes certain non-GAAP financial measures. These non-GAAP financial measures should not be considered in isolation or a substitute for the comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the Appendix of this presentation. This presentation contains statements that are, or may be deemed to be, forward ...

Neonode Inc. (NASDAQ: NASDAQ: NEON ) is a Sweden-based technology company specializing in optical sensing and gesture recognition. After dumping hardware, Neonode rebranded itself as a straight licensing shop, built around its zForce and MultiSensing tech. The idea is to wedge itselfI focus on producing objective, data-driven research, mostly about small- to mid-cap companies, as these tend to be overlooked by many investors. From time to time, though, I also look at large-cap names, just to give a fuller s ...

Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix’s strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on adva ...

STOCKHOLM, June 3, 2025 /PRNewswire/ -- Neonode Inc. (NASDAQ: NEON) (the "Company" or "Neonode") will be added as a member of the U.S. small-cap Russell 2000 Index, effective after the U.S. market opens on June 30 as part of the 2025 Russell indexes reconstitution. Neonode, a provider of touch technology and optical sensing solutions for technologically demanding and regulated industries, debuted on the NASDAQ stock exchange in 2012 under the stock ticker symbol "NEON."Membership in the Russell 2000 Index, ...